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The contents of the report are the author's own views and do not necessarily reflect the views of the Korean Circulation Journal. and 11.4±1.0% and 25.7±1.4% in the controls; 3-and 5-year cardiac mortality rates were 38.2±3.8% and 50.7±4.3% in severe AS patients, and 3.0±0.6% and 6.4±0.8% in the controls, respectively. More importantly, cardiac mortality accounted for around 90% of the deaths in severe AS patients, compared to around 25% of the deaths in normal controls. This study found a lower mortality rate than previous studies did: one-year mortality rates ranged from 33.5% in one study of unoperated symptomatic severe AS patients, 4) 38% in another study of unoperated severe AS patients, 6) up to 50.7% in inoperable symptomatic severe AS patients in the Placement of Aortic Transcatheter Valves (PARTNER) trial. 7) One main reason may be that the study by Oh et al. 5) enrolled the 'younger' elderly AS patients (78±7 years), whereas the mean age of AS patients enrolled in the PARTNER trial was 83.1±8.6 years. Since age itself is one of the most important unmodifiable risk factors of mortality, it seems that the study by Oh et al. 5) recruited AS patients at a somewhat lower risk. Also, the patients in this study had a lower prevalence of comorbidities compared to other studies. One limitation of this study, as the authors acknowledged, was that 11 patients who were unable to be contacted by the physician were presumed to have died of cardiac causes. This may be one reason why cardiac mortality was unexpectedly high. It would also have been more fruitful and persuasive if outcomes were compared with age-and sex-matched severe AS patients who received SAVR or TAVR; these analyses would have objectively strengthened the rationale for active treatment in severe 'symptomatic' AS patients.
Finally, one issue that is worthy of being mentioned is that this study found no significant differences in all-cause and cardiac mortality among groups stratified by trans-aortic valve pressure gradient and LVEF (i.e., high-gradient severe AS with preserved/depressed LVEF and low-gradient severe AS with preserved/depressed LVEF). Low-gradient severe AS with preserved LVEF is not easy to diagnose, and multimodality imaging approach can be preferable in confirming the role of severe AS in provoking symptoms. 8) According to data provided by Oh et al., 5) all types of symptomatic severe AS resulted in grave prognosis if untreated, and thus, the diseased aortic valve should be replaced in a timely fashion regardless of the pressure gradient or flow type.
5) However, we also need to remember an earlier report suggesting that the outcome of low-gradient severe AS with preserved LVEF was similar to that of mild to moderate AS and was not favorably affected by SAVR. 9) This issue requires further investigation in Korean severe AS patients.
Natural history data in severe AS is now difficult to obtain, because there is no doubt that SAVR has been established as a life-saving treatment, and thus, it is unethical not to refer severe symptomatic AS patients to corrective surgery. Besides, TAVR is a reliable plan B in severe AS patients at intermediate or high surgical risk and those who refuse SAVR. In this respect, this study provides a last opportunity to remind us of the importance of timely referral for SAVR or TAVR in severe AS. As there is no doubt that symptomatic severe AS confers a grave prognosis, necessity of corrective AS surgery should again be highlighted. Undoubtedly, less invasive radical treatments such as TAVR or suture-less SAVR are opening a new chapter in the treatment of severe AS. With these new treatment options, we hope that the majority of elderly AS patients can enjoy the benefit of aortic valve replacement in terms of quality of life and longevity.
